In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CardioLogical Solutions

Division of Emboline Inc.
www.cardiologicalsolutions.com

Latest From CardioLogical Solutions

Cerebral Embolic Protection For TAVR: Start-Ups Compete

With minimally invasive left-heart procedures like transcatheter aortic valve replacement becoming increasingly safe and commonplace, attention has turned to procedure-associated brain injury from showers of emboli. Several medtech start-ups are developing devices that could protect patients’ brains during not only TAVR, but also surgical aortic valve replacement, atrial fibrillation ablation and other left-heart procedures.

Medical Device

Stroke Prevention For TAVR – And, Perhaps, Beyond

Although TAVR-related stroke rates have been diminishing, it remains a devastating complication of the procedure. Two companies with devices to deflect or collect emboli are embarking on IDE trials that they hope will make cerebral embolic protection a standard of care in TAVR and perhaps other cardiac surgeries, as it already is in carotid artery stenting.

Medical Device

Stroke Prevention For TAVR – And, Perhaps, Beyond

Although TAVR-related stroke rates have been diminishing, it remains a devastating complication of the procedure. Two companies with devices to deflect or collect emboli are embarking on IDE trials that they hope will make cerebral embolic protection a standard of care in TAVR and perhaps other cardiac surgeries, as it already is in carotid artery stenting.

Medical Device Deals

Micro Interventional Devices’ Permaseal Moves Closer To Regulatory Approval With Early CE Trial Results

Preliminary 30-day results from the Secure Transapical Access and Closure Study (STASIS) suggest Micro Interventional Devices’ Permaseal device, a transapical access and closure device for structural heart repair, provides safe and effective hemostasis and wound closure after transapical transcatheter aortic valve replacement. The company estimates the worldwide market potential for the device is more than $3 billion annually.

Medical Device Innovation
See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • VasoStitch Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Emboline Inc.
  • Senior Management
  • David Smith, Pres. & CEO
  • Contact Info
  • CardioLogical Solutions
    Phone: (510) 225-9258
    2013 Swan St.
    Danville, CA 94506
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register